A4250 (odevixibat)
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Familial Intrahepatic Cholestasis
Conditions
Progressive Familial Intrahepatic Cholestasis
Trial Timeline
Sep 28, 2018 → Dec 2, 2025
NCT ID
NCT03659916About A4250 (odevixibat)
A4250 (odevixibat) is a phase 3 stage product being developed by Ipsen for Progressive Familial Intrahepatic Cholestasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03659916. Target conditions include Progressive Familial Intrahepatic Cholestasis.
What happened to similar drugs?
2 of 20 similar drugs in Progressive Familial Intrahepatic Cholestasis were approved
Approved (2) Terminated (4) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03659916 | Phase 3 | Completed |
Competing Products
20 competing products in Progressive Familial Intrahepatic Cholestasis